This is an old revision of this page, as edited by Pashihiko (talk | contribs) at 08:07, 19 January 2011. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 08:07, 19 January 2011 by Pashihiko (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Other names | 1-De(5-oxo-L-proline)-2-de-L-glutamine- 5-L-methioninecaerulein, 3--3-(4-sulfooxyphenyl)propanoyl]amino]-4- methylsulfanyl-butanoyl]amino]acetyl]amino]-3- (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl- butanoyl]amino]-3-propanoic acid |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.042.384  |
| Chemical and physical data | |
| Formula | C49H62N10O16S3 |
| Molar mass | 1143.27 g/mol g·mol |
Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.
Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.
External links
- KINEVAC (sincalide) on NIH.gov
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |